Role of Guduchyadi Ghrita in the management of the Mild Neurocognitive Disorder.
- Conditions
- Health Condition 1: G318- Other specified degenerative diseases of nervous system
- Registration Number
- CTRI/2023/04/051695
- Lead Sponsor
- Institute of Teaching and Research in Ayurveda
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1) Subjects irrespective of gender, fulfilling the criteria of Mild Neurocognitive Disorder as per DSM V.
2) Age group â?? 40 - 70 years
3) Montreal Cognitive Assessment scale [MoCA] (18 to 25)
4) Patients willing to accept participation in the clinical trial.
1) Age below 40 years and above 70 years.
2) Subjects with major depression or other psychiatric disorders or currently undergoing treatment for depression.
3) Use of psychoactive medication that would affect the subjectâ??s ability to reliably perform on neurocognitive testing.
4) Subjects with Malignant disease, HIV or serious infection.
5) Subjects with Cardiovascular, Renal or Hepatic disorder, Thyroid dysfunction.
6)subjects with Stage II HTN or above (Blood Pressure >160/100 mm of Hg), Diabetes (FBS >200 mg/dl), Dyslipidemia (Severe Hypertriglyceridemia,TG >500 mg/dl and /or, LDL >190 mg/dl)
7) Subjects who have decline in cognitive functions as a result of surgery and trauma.
8) Visual/auditory impairment that would preclude the participant from participating in or cooperating with the protocol.
9) Pregnant women and lactating mothers.
10) Patient with alcohol abuse.
11) Subjects who are not able to read, write and comprehend Hindi language properly for comprehending the assessment tests.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement in cognitionTimepoint: At baseline ,4th week , 8th week , 10th week , 12 th week
- Secondary Outcome Measures
Name Time Method Improvement of quality of life of the patients with mild Neurocognitive DisorderTimepoint: Baseline and 8th week